Proxy Votes Now

Home › Funds › Fidelity › Select Biotechnology Portfolio

Select Biotechnology Portfolio (FBIOX) proxy voting record 2025-2026

Fund family: Fidelity · Filed by FIDELITY SELECT PORTFOLIOS (CIK 320351) · SEC series S000007486

Ticker: FBIOX (C000020460)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,066 with, 6 against, 4 abstentions (not counted as with management); 2 items carried no recommendation. Shareholder proposals: 2 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Fidelity as a whole

The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsFidelityItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)86.4%1,00894.1%974,562
Backed environmental and social shareholder proposals at US companiesn/a26.8%11,096

Where this fund voted differently from most Fidelity funds

Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Fidelity funds on 61 items (6.1% of the 998 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Fidelity fundsMgmtResult
Perspective Therapeutics, Inc.2026-05-27Election of Directors: Robert Froman Williamson, IIIForWITHHOLD — 10 of 10 Fidelity fundsForPassed (calculated), 87.9% support
ARS Pharmaceuticals, Inc.2026-06-24To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Laura Shawver, Ph.D.WithholdFOR — 13 of 14 Fidelity fundsAgainstElected, 68.4% support
BioCryst Pharmaceuticals, Inc.2026-06-11To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan.AgainstFOR — 16 of 18 Fidelity fundsAgainstApproved, 65.4% support
Ultragenyx Pharmaceutical Inc.2026-05-14Nominees: Daniel G. WelchWithholdFOR — 16 of 18 Fidelity fundsAgainstPassed (calculated), 90.1% support
Ultragenyx Pharmaceutical Inc.2026-05-14Nominees: Emil D. Kakkis, M.D., Ph.D.WithholdFOR — 16 of 18 Fidelity fundsAgainstPassed (calculated), 98.6% support
Ultragenyx Pharmaceutical Inc.2026-05-14Nominees: Shehnaaz Suliman, M.D.WithholdFOR — 16 of 18 Fidelity fundsAgainstPassed (calculated), 89.4% support
Ultragenyx Pharmaceutical Inc.2026-05-14Approval of the Third Amended and Restated 2023 Incentive Plan.AgainstFOR — 15 of 17 Fidelity fundsAgainstApproved, 68.9% support
ARS Pharmaceuticals, Inc.2026-06-24To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.ForAGAINST — 15 of 17 Fidelity fundsForApproved, 87.6% support
Inhibikase Therapeutics, Inc.2026-06-26to elect two Class III directors, to the Board of Directors, each to serve until the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Arvind KushWithholdFOR — 7 of 7 Fidelity fundsAgainstElected, 84.6% support
TG Therapeutics, Inc.2026-06-11Election of Directors: Daniel HumeWithholdFOR — 14 of 16 Fidelity fundsAgainstPassed (calculated), 78.6% support
TG Therapeutics, Inc.2026-06-11Election of Directors: Laurence CharneyWithholdFOR — 14 of 16 Fidelity fundsAgainstPassed (calculated), 83.7% support
TG Therapeutics, Inc.2026-06-11Election of Directors: Yann EchelardWithholdFOR — 14 of 16 Fidelity fundsAgainstPassed (calculated), 78.7% support
Corcept Therapeutics Incorporated2026-05-21To approve an amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan to increase the number of shares available thereunder and clarify certain other language in the plan.AgainstFOR — 20 of 25 Fidelity fundsAgainstApproved, 69.0% support
Corcept Therapeutics Incorporated2026-05-21Election of Directors: David L. MahoneyForWITHHOLD — 19 of 24 Fidelity fundsForElected, 66.1% support
Allogene Therapeutics, Inc.2026-06-18Election of Directors: Owen Witte, M.D.ForWITHHOLD — 12 of 14 Fidelity fundsForElected, 82.9% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Laura BregeWithholdFOR — 14 of 17 Fidelity fundsAgainstElected, 95.8% support
Ionis Pharmaceuticals, Inc.2026-06-04To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.AgainstFOR — 25 of 34 Fidelity fundsAgainstApproved, 77.0% support
BioCryst Pharmaceuticals, Inc.2026-06-11To hold a non-binding, advisory vote regarding executive compensation.ForAGAINST — 15 of 19 Fidelity fundsForApproved, 68.9% support
Prothena Corporation plc2026-05-14To elect, by separate resolutions, two directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2029, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Dennis J. SelkoeAgainstFOR — 12 of 15 Fidelity fundsAgainstElected, 72.8% support
Prothena Corporation plc2026-05-14To elect, by separate resolutions, two directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2029, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Shane M. CookeAgainstFOR — 12 of 15 Fidelity fundsAgainstElected, 65.6% support
TG Therapeutics, Inc.2026-06-11Election of Directors: Sagar Lonial, MDWithholdFOR — 13 of 17 Fidelity fundsAgainstPassed (calculated), 54.9% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D.WithholdFOR — 13 of 17 Fidelity fundsAgainstElected, 70.3% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Jonathan Root, M.D.WithholdFOR — 13 of 17 Fidelity fundsAgainstElected, 65.0% support
Capricor Therapeutics, Inc.2026-06-04ELECTION OF DIRECTORS: Frank LitvackWithholdFOR — 13 of 17 Fidelity fundsAgainstPassed (calculated), 68.6% support
Cartesian Therapeutics, Inc.2026-06-12Election of Directors: Timothy A. Springer, Ph.D.WithholdFOR — 7 of 8 Fidelity fundsAgainstElected, 94.1% support
Show all 61
Items 26 to 61.
CompanyMeetingItemThis fundMost Fidelity fundsMgmtResult
Sana Biotechnology, Inc.2026-06-04To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Hans E. BishopWithholdFOR — 13 of 17 Fidelity fundsAgainst—
Edgewise Therapeutics, Inc.2026-06-04Conduct an advisory vote on the compensation of our named executive officers.AgainstFOR — 14 of 19 Fidelity fundsAgainstApproved, 96.1% support
Tectonic Therapeutic, Inc.2026-06-08Election of Directors: Timothy A. Springer, Ph.D.WithholdFOR — 12 of 16 Fidelity fundsAgainstPassed (calculated), 79.5% support
Forte Biosciences, Inc.2026-05-29The approval of the Company's Amended and Restated 2021 Equity Incentive Plan.AgainstFOR — 4 of 4 Fidelity fundsAgainstApproved, 74.9% support
vTv Therapeutics Inc.2026-06-26To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Anne M. PhillipsWithholdFOR — 4 of 4 Fidelity fundsAgainst—
vTv Therapeutics Inc.2026-06-26To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Daniel K. SpiegelmanWithholdFOR — 4 of 4 Fidelity fundsAgainst—
vTv Therapeutics Inc.2026-06-26To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Fahed Al MarzooqiWithholdFOR — 4 of 4 Fidelity fundsAgainst—
vTv Therapeutics Inc.2026-06-26To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Paul SekhriWithholdFOR — 4 of 4 Fidelity fundsAgainst—
vTv Therapeutics Inc.2026-06-26To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Richard S. NelsonWithholdFOR — 4 of 4 Fidelity fundsAgainst—
Roivant Sciences Ltd.2025-09-10To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Keith ManchesterWithholdFOR — 16 of 24 Fidelity fundsAgainstElected, 70.6% support
Roivant Sciences Ltd.2025-09-10To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Matthew GlineWithholdFOR — 16 of 24 Fidelity fundsAgainstElected, 73.6% support
Roivant Sciences Ltd.2025-09-10To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Melissa EpperlyWithholdFOR — 16 of 24 Fidelity fundsAgainstElected, 73.5% support
Nuvation Bio Inc.2026-05-21Election of Directors: Robert BazemoreForWITHHOLD — 12 of 17 Fidelity fundsForElected, 84.0% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Kenneth A. ClarkWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 96.1% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Mahkam ZanganehWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 98.5% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Manmeet S. SoniWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 98.4% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Robert W. DugganWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 98.3% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Yu (Michelle) XiaWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 98.3% support
Summit Therapeutics Inc.2026-06-10Approval, by a non-binding advisory vote, of the compensation of our named executive officers.ForAGAINST — 17 of 27 Fidelity fundsForPassed (calculated), 96.2% support
Atea Pharmaceuticals, Inc.2026-06-18Election of Class III Directors: Jerome Adams, MD, MPHWithholdFOR — 12 of 18 Fidelity fundsAgainstPassed (calculated), 56.4% support
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: Hongbo LuAgainstFOR — 14 of 22 Fidelity fundsAgainst—
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: William WaddillAgainstFOR — 14 of 22 Fidelity fundsAgainstPassed (calculated), 90.3% support
Palvella Therapeutics, Inc.2026-06-10Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. DavisWithholdFOR — 9 of 13 Fidelity fundsAgainstPassed (calculated), 81.8% support
Rezolute, Inc.2025-11-19To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Erik HarrisWithholdFOR — 12 of 19 Fidelity fundsAgainstPassed (calculated), 81.2% support
Rezolute, Inc.2025-11-19To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Nerissa KreherWithholdFOR — 12 of 19 Fidelity fundsAgainstPassed (calculated), 76.6% support
Foghorn Therapeutics Inc.2026-06-24Elect Class III directors each for a three-year term: Douglas Cole, M.D.AgainstFOR — 7 of 10 Fidelity fundsAgainstElected, 76.2% support
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: Michael S. PerryAgainstFOR — 13 of 22 Fidelity fundsAgainst—
uniQure N.V.2026-06-10Resolution to adopt the amendment to the Articles of Association to reflect Dutch large company regime.ForAGAINST — 10 of 16 Fidelity fundsForApproved, 74.5% support
Forte Biosciences, Inc.2026-05-29The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote").ForAGAINST — 4 of 5 Fidelity fundsForApproved, 76.3% support
Nurix Therapeutics, Inc.2026-05-15Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.WithholdFOR — 13 of 24 Fidelity fundsAgainstElected, 79.6% support
Nurix Therapeutics, Inc.2026-05-15Election of Class III Directors: Paul M. SilvaWithholdFOR — 13 of 24 Fidelity fundsAgainstElected, 74.2% support
Stoke Therapeutics, Inc.2026-06-03Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne SmithWithholdFOR — 14 of 27 Fidelity fundsAgainstPassed (calculated), 86.9% support
Biomea Fusion, Inc.2026-06-10The election of Rainer (Ramses) Erdtmann and Eric Aguiar, M.D., as Class II Directors, to serve for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029: Rainer (Ramses) ErdtmannWithholdFOR — 4 of 7 Fidelity fundsAgainst—
CAMP4 Therapeutics Corporation2026-06-10Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Murray Stewart, DM FRCPAgainstFOR — 4 of 7 Fidelity fundsAgainst—
CAMP4 Therapeutics Corporation2026-06-10Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Richard Young, PhDAgainstFOR — 4 of 7 Fidelity fundsAgainst—
CAMP4 Therapeutics Corporation2026-06-10Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Steven HoltzmanAgainstFOR — 4 of 7 Fidelity fundsAgainst—

Download all 61 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 72.1% of this fund’s 1,076 such votes could be given a sector; the other 300 (27.9%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care77660.8%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5770
Audit-related1590
Say-on-Pay1380
Compensation860
Capital Structure730
Corporate Governance634
Extraordinary Transactions20
Other Social Issues21
Shareholder Rights and Defenses20
Environment or Climate11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
AbbVie Inc.May 8, 2026$754M81
Amgen Inc.May 19, 2026$530M151
Gilead Sciences, Inc.April 30, 2026$527M153
Krystal Biotech, Inc.May 15, 2026$520M50
argenx SENovember 18, 2025$157M10
Moderna, Inc.November 12, 2025$120M20
Praxis Precision Medicines, Inc.June 10, 2026$120M50
Insmed IncorporatedMay 13, 2026$114M40

Notable votes against management

MeetingCompanyProposalFundMgmt
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor

Search this fund’s votes by company

1,103 ballot items at 159 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Select Biotechnology Portfolio (FBIOX) voted at 159 shareholder meetings of 153 companies, on 1,103 ballot items in all. Where management made a recommendation, the fund followed it on 99.1% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 8 shareholder proposals. It voted FOR the board's own proposals less often than Fidelity's funds as a whole (86.4% against 94.1%). It voted differently from most Fidelity funds on 61 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.